Retinal Vein Occlusions

Ophthalmology

Volumn 123, Issue 1, 2016, Pages P182-P208

  Pulido, Jose S ^a   Flaxel, Christina J ^b   Adelman, Ron A ^c   Hyman, Leslie ^d   Folk, James C ^e   Olsen, Timothy W ^f  

^a MAYO CLINIC   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d STONY BROOK UNIVERSITY   (United States)

^e UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^f EMORY EYE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EARLY DIAGNOSIS; ECHOOCULOGRAPHY; EYE SURGERY; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; INCIDENCE; LASER COAGULATION; MEDICAL HISTORY; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; PATIENT CARE; PATIENT COUNSELING; PATIENT REFERRAL; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA VEIN OCCLUSION; REVIEW; RISK FACTOR; SOCIOECONOMICS; TREATMENT OUTCOME; CLINICAL PRACTICE; DISEASE MANAGEMENT; OPHTHALMOLOGY; RETINAL VEIN OCCLUSION; STANDARDS;

DISEASE MANAGEMENT; HUMANS; OPHTHALMOLOGY; PRACTICE PATTERNS, PHYSICIANS'; RETINAL VEIN OCCLUSION;

EID: 84951908181     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2015.10.045     Document Type: Article

References (91)

1. Scottish Intercollegiate Guidelines Network. Annex B: key to evidence statements and grades of recommendations. In: SIGN 50: A Guideline Developer's Handbook. 2008 edition, revised 2011. Edinburgh, Scotland: Scottish Intercollegiate Guidelines Network. Available at: www.sign.ac.uk/guidelines/fulltext/50/index.html. Accessed June 26, 2015.
2. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6.
3. GRADE Working Group. Organizations that have endorsed or that are using GRADE. Available at: www.gradeworkinggroup.org/society/index.htm. Accessed January 14, 2015.
4. Buehl W, Sacu S, Schmidt-Erfurth U. Retinal vein occlusions. Dev Ophthalmol 2010;46:54-72.
5. Weinberg D, Dodwell DG, Fern SA. Anatomy of arteriovenous crossings in branch retinal vein occlusion. Am J Ophthalmol 1990;109:298-302.
6. Kumar B, Yu DY, Morgan WH, et al. The distribution of angioarchitectural changes within the vicinity of the arteriovenous crossing in branch retinal vein occlusion. Ophthalmology 1998;105:424-7.
7. Sanborn GE, Magargal LE. Characteristics of the hemispheric retinal vein occlusion. Ophthalmology 1984;91:1616-26.
8. Hayreh SS, Hayreh MS. Hemi-central retinal vein occulsion. Pathogenesis, clinical features, and natural history. Arch Ophthalmol 1980;98:1600-9.
9. Central Vein Occlusion Study Group. Baseline and early natural history report: the Central Vein Occlusion Study. Arch Ophthalmol 1993; 111:1087-95.
10. Rogers S, Mcintosh RL, Cheung N, et al, International Eye Disease Consortium. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010;117:313-9.
11. Jaulim A, Ahmed B, Khanam T, Chatziralli IP. Branch retinal vein occlusion: epidemiology, pathogenesis, risk factors, clinical features, diagnosis, and complications: an update of the literature. Retina 2013;33:901-10.
12. Zhou JQ, Xu L, Wang S, et al. The 10-year incidence and risk factors of retinal vein occlusion: the Beijing eye study. Ophthalmology 2013;120:803-8.
13. Jonas JB, Nangia V, Khare A, et al. Prevalence and associations of retinal vein occlusions: the Central India Eye and Medical Study. Retina 2013;33:152-9.
14. Arakawa S, Yasuda M, Nagata M, et al. Nine-year incidence and risk factors for retinal vein occlusion in a general Japanese population: the Hisayama Study. Invest Ophthalmol Vis Sci 2011;52:5905-9.
15. Park SJ, Choi NK, Seo KH, et al. Nationwide incidence of clinically diagnosed central retinal artery occlusion in Korea, 2008 to 2011. Ophthalmology 2014;121:1933-8.
16. Yen YC, Weng SF, Chen HA, Lin YS. Risk of retinal vein occlusion in patients with systemic lupus erythematosus: a population-based cohort study. Br J Ophthalmol 2013;97:1192-6.
17. Central Vein Occlusion Study Group. Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 1997;115:486-91.
18. Hayreh SS, Zimmerman MB, Podhajsky P. Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Am J Ophthalmol 1994;117:429-41.
19. Michels RG, Gass JD. The natural course of retinal branch vein obstruction. Trans Am Acad Ophthalmol Otolaryngol 1974;78:OP166-77.
20. Eye Disease Case-Control Study Group. Risk factors for central retinal vein occlusion Arch Ophthalmol 1996;114:545-54.
21. Hayreh SS, Zimmerman B, McCarthy MJ, Podhajsky P. Systemic diseases associated with various types of retinal vein occlusion. Am J Ophthalmol 2001;131:61-77.
22. Hayreh SS, Zimmerman MB, Beri M, Podhajsky P. Intraocular pressure abnormalities associated with central and hemicentral retinal vein occlusion. Ophthalmology 2004;111:133-41.
23. Chou KT, Huang CC, Tsai DC, et al. Sleep apnea and risk of retinal vein occlusion: a nationwide population-based study of Taiwanese. Am J Ophthalmol 2012;154:200-5.
24. Fong AC, Schatz H. Central retinal vein occlusion in young adults. Surv Ophthalmol 1993;37:393-417.
25. Tourville E, Schachat AP. Plasma proteins-possible risk factors for retinal vascular occlusive disease. In: Joussen AM, Gardner TW, Kirchhof B, Ryan SJ, eds. Retinal Vascular Disease. 1st ed. Berlin; New York: Springer-Verlag; 2007.
26. Bertelsen M, Linneberg A, Christoffersen N, et al. Mortality in patients with central retinal vein occlusion. Ophthalmology 2014;121:637-42.
27. Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc 2000;98:133-41; discussion 141-3.
28. Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 1984;98:271-82.
29. Christoffersen NL, Larsen M. Pathophysiology and hemodynamics of branch retinal vein occlusion. Ophthalmology 1999;106:2054-62.
30. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion: the Central Vein Occlusion Study Group N report. Ophthalmology 1995;102:1434-44.
31. Iliev ME, Domig D, Wolf-Schnurrbursch U, et al. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 2006;142:1054-6.
32. Chatziralli IP, Jaulim A, Peponis VG, et al. Branch retinal vein occlusion: treatment modalities: an update of the literature. Semin Ophthalmol 2014;29:85-107.
33. Scott IU, Ip MS, VanVeldhuisen PC, et al, SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 2009;127:1115-28.
34. Ip MS, Scott IU, VanVeldhuisen PC, et al, SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009;127:1101-14.
35. Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010;117:1124-33.
36. Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 2011;118:2041-9.
37. Heier JS, Campochiaro PA, Yau L, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology 2012;119:802-9.
38. Boyer D, Heier J, Brown DM, et al. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology 2012;119:1024-32. Erratum in: Ophthalmology 2012;! 19:204.
39. Brown DM, Heier JS, Clark WL, et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol 2013;155:429-37.
40. Holz FG, Roider J, Ogura Y, et al. VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. Br J Ophthalmol 2013;97:278-84.
41. Epstein DL, Algvere PV, von Wendt G, et al. Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study. Ophthalmology 2012;119:1184-9.
42. Epstein DL, Algvere PV, von Wendt G, et al. Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study. Ophthalmology 2012;119:2587-91.
43. Zhang H, Liu ZL, Sun P, Gu F. Intravitreal bevacizumab for treatment of macular edema secondary to central retinal vein occlusion: eighteen-month results of a prospective trial. J Ocul Pharmacol Ther 2011;27:615-21.
44. Kriechbaum K, Michels S, Prager F, et al. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol 2008;92:518-22.
45. Prager F, Michels S, Kriechbaum K, et al. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol 2009;93:452-6.
46. O'Mahoney PR, Wong DT, Ray JG Retinal vein occlusion and traditional risk factors for atherosclerosis. Arch Ophthalmol 2008;126:692-9.
47. Branch Vein Occlusion Study Group. Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion: a randomized clinical trial. Arch Ophthalmol 1986;104:34-41.
48. American Academy of Ophthalmology Preferred Practice Patterns Committee. Preferred Practice Pattern Guidelines. Comprehensive Adult Medical Eye Evaluation. San Francisco, CA: American Academy of Ophthalmology; 2015. Available at: www.aao.org/ppp.
49. Davis MD, Bressler SB, Aiello LP, et al, Diabetic Retinopathy Clinical Research Network Study Group. Comparison of time-domain OCT and fundus photographic assessments of retinal thickening in eyes with diabetic macular edema. Invest Ophthalmol Vis Sci 2008;49:1745-52.
50. Yannuzzi LA, Rohrer KT, Tindel LJ, et al. Fluorescein angiography complication survey. Ophthalmology 1986;93:611-7.
51. Sunness JS. The pregnant woman's eye. Surv Ophthalmol 1988;32:219-38.
52. Ehlers JP, Fekrat S. Retinal vein occlusion: beyond the acute event. Surv Ophthalmol 2011;56:281-99.
53. Haller JA, Bandello F, Belfort R Jr, et al, Ozurdex GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117:1134-46.
54. Haller JA, Bandello F, Belfort R Jr, et al, Ozurdex GENEVA Study Group. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011;118:2453-60.
55. Jain N, Stinnett SS, Jaffe GJ. Prospective study of a fluocinolone acetonide implant for chronic macular edema from central retinal vein occlusion: thirty-six-month results. Ophthalmology 2012;119:132-7.
56. Campochiaro PA, Heier JS, Feiner L, et al, BRAVO Investigators. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010;117:1102-12.
57. Brown DM, Campochiaro PA, Bhisitkul RB, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 2011; 118:1594-602.
58. Yilmaz T, Cordero-Coma M. Use of bevacizumab for macular edema secondary to branch retinal vein occlusion: a systematic review. Graefes Arch Clin Exp Ophthalmol 2012;250:787-93.
59. Russo V, Barone A, Conte E, et al. Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion. Retina 2009;29:511-5.
60. ClinicalTrials.gov. Study to assess the clinical efficacy and safety of intravitreal aflibercept Injection (IAI;EYLEA® ;BAY86-5321) in patients with branch retinal vein occlusion (BRVO) (VIBRANT). November 2014. Available at: https://clinicaltrials.gov/ct2/show/study/NCT01521559. Accessed May 15,2015.
61. Parke DWII, Coleman AL, Rich WL III, Lum F. Choosing Wisely: five ideas that physicians and patients can discuss. Ophthalmology 2013;120:443-4.
62. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy: ETDRS report number 9. Ophthalmology 1991;98:766-85.
63. Jacobson DR, Murphy RP, Rosenthal AR. The treatment of angle neovascularization with panretinal photocoagulation. Ophthalmology 1979;86:1270-7.
64. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985;103:1796-806.
65. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy: ETDRS report number 12. Ophthalmology 1991;98:823-33.
66. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002;287:2563-9.
67. Elman MJ, Qin H, Aiello LP, et al, Diabetic Retinopathy Clinical Research Network. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology 2012;119:2312-8.
68. Chew EY, Klein ML, Ferris FL III, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy: Early Treatment Diabetic Retinopathy Study (ETDRS) report 22. Arch Ophthalmol 1996;114:1079-84.
69. Brown DM, Nguyen QD, Marcus DM, et al, RIDE and RISE Research Group. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013;120:2013-22.
70. Nguyen QD, Shah SM, Khwaja AA, et al, READ-2 Study Group. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology 2010;117:2146-51.
71. Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol 2012;130:972-9.
72. Do DV, Nguyen QD, Boyer D, et al, DA VINCI Study Group. One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology 2012; 119:1658-65.
73. Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 2. Ophthalmology 1987;94:761-74.
74. Fong DS, Ferris FL III, Davis MD, Chew EY, Early Treatment Diabetic Retinopathy Study Research Group. Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Am J Ophthalmol 1999;127:137-41.
75. Sivaprasad S, Crosby-Nwaobi R, Heng LZ, et al. Injection frequency and response to bevacizumab monotherapy for diabetic macular oedema (BOLT report 5). Br J Ophthalmol 2013;97:1177-80.
76. Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy: clinical application of Diabetic Retinopathy Study (DRS) findings, DRS report number 8. Ophthalmology 1981;88:583-600.
77. Turner RC. The U.K. Prospective Diabetes Study: a review. Diabetes Care 1998;21 (suppl):C35-8.
78. Nathan DM, Bayless M, Cleary P, et al, DCCT/EDIC Research Group. Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions. Diabetes 2013;62:3976-86.
79. Ismail-Beigi F, Craven T, Banerji MA, et al, ACCORD Trial Group. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010;376:419-30.
80. Erratum in: Lancet 2010;376:1466.
81. Bressler SB, Qin H, Melia M, et al, Diabetic Retinopathy Clinical Research Network. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. JAMA Ophthalmol 2013;131:1033-40.
82. Diabetic Retinopathy Clinical Research Network Authors/Writing Committee. Macular edema after cataract surgery in eyes without preoperative central-involved diabetic macular edema. JAMA Ophthalmol 2013;131:870-9.
83. American Academy of Ophthalmology. Clinical Statement. Intravitreal Injections. San Francisco, CA: American Academy of Ophthalmology; 2015. Available at: www.aao.org/guidelines-browsefirter=clinicalstatement. Accessed July 10, 2015.
84. Simcock P, Kingett B, Mann N, et al. A safety audit of the first 10 000 intravitreal ranibizumab injections performed by nurse practitioners. Eye (Lond) 2014;28:1161-4.
85. DaCosta J, Hamilton R, Nago J, et al. Implementation of a nurse-delivered intravitreal injection service. Eye (Lond) 2014;28:734-40.
86. Hasler PW, Bloch SB, Villumsen J, et al. Safety study of 38,503 intravitreal ranibizumab injections performed mainly by physicians in training and nurses in a hospital setting. Acta Ophthalmol 2015;93:122-5.
87. American Academy of Ophthalmology. Clinical Statement. Eye MD Examination Report Form. San Francisco, CA: American Academy of Ophthalmology; 2005; Reviewed 2012. Available at: www.aao.org/guidelines-browse7filteFclinicalstatement. Accessed January 14, 2015.
88. American Academy of Ophthalmology Vision Rehabilitation Committee. Preferred Practice Pattern® Guidelines. Vision Rehabilitation. San Francisco, CA: American Academy of Ophthalmology; 2013. Available at: www.aao.org/ppp.
89. Stelmack JA, Tang XC, Reda DJ, et al, LOVIT Study Group. Outcomes of the Veterans Affairs Low Vision Intervention Trial (LOVIT). Arch Ophthalmol 2008;126:608-17.
90. Smiddy WE. Economic considerations of macular edema therapies. Ophthalmology 2011;118:1827-33.
91. Suner IJ, Margolis J, Ruiz K, et al. Direct medical costs and resource use for treating central and branch retinal vein occlusion in commercially insured working-age and Medicare populations. Retina 2014;34:2250-8.